ACOR : Analysis & Opinions

  1. AMAG, Takeda Mutually End Agreement for Feraheme - Analyst Blog

    December 30, 2014
    AMAG Pharmaceuticals (AMAG) and Takeda (TKPYY) mutually terminate their licensing deal for Ferahame in the ex-U.S. territories ...
  2. BioMarin's Vimizim OK'd in Japan for Morquio A Syndrome - Analyst ...

    December 30, 2014
    BioMarin's (BMRN) Vimizim gained Japanese approval for the treatment of patients suffering from mucopolysaccharidosis type ...
  3. Cyberonics: VNS Therapy Strong, Reimbursement Woes Stay - Analyst ...

    December 30, 2014
    On Dec 29, we issued an updated research report on Cyberonics Inc. (CYBX).
  4. Qiagen Poised on Molecular Diagnostics, International Strength ...

    December 30, 2014
    On Dec 30, we issued an updated research report on Qiagen N.V. (QGEN).
  5. Acorda's Ampyra in Phase III for Post-Stroke Walking Deficit ...

    December 16, 2014
    Acorda (ACOR) has commenced a phase III study on Ampyra for the treatment of post-stroke walking deficits.
Trading Center